- Home
- A-Z Publications
- Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
- Previous Issues
- Volume 8, Issue 4, 2010
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 8, Issue 4, 2010
Volume 8, Issue 4, 2010
-
-
Nutriproteomics - Linking Proteomics Variation with Personalized Nutrition
More LessNutrition research has traditionally focused on providing adequate amounts of nutrients to nourish populations and prevent nutrient deficiencies. Modern nutrition science explores health-related aspects of bioactive components in foodstuffs at a subgroup rather than population level. Today's nutrition research focuses on promoting health, preventing or delaying the onset of disease, optimizing performance and assessing risk i Read More
-
-
-
Systems Biology and Synthetic Biology: Understanding Biological Complexity on the Critical Path to Personalized Medicine
More LessIt has been suggested that personalized medicine era is fast approaching based on recent applied genomics and life sciences findings. But are the tools to enable personalized therapeutics and multiplexed diagnostics at hand? Nearly a decade after the first full publication of the human genome sequence and the media hype around numerous related medical promises, biologists are still facing crucial questions about biological co Read More
-
-
-
Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing
Authors: Sara D. Brouse, John C. Fullerton and Majid MoridaniOver the past several years, it has become evident that not all patients respond optimally to standard dosing of the antiplatelet medication clopidogrel. With the aid of pharmacogenetics research, polymorphisms in the CYP2C19 gene (*2, *3, *4, *5,*6, *7, *8) have been linked with the poor conversion of clopidogrel to its active metabolite and reduced clopidogrel efficacy. Poor response to clopidogrel therapy as evidenc Read More
-
-
-
Pharmacogenomics of Multiple Sclerosis: Current Status and Potential Applications
Authors: Masaaki Niino and Seiji KikuchiIn the past decade, treatment for multiple sclerosis (MS), especially with respect to disease modifying therapies (DMTs), has substantially improved. Responses to DMTs, such as interferon β and glatiramer acetate, are not uniform, with considerable variability seen in efficacy and toxicity. Furthermore, unexpected serious side effects have been reported for recently developed therapies. There are currently no reliable mar Read More
-
-
-
Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes
Authors: Tai-Chung Tseng, Chun-Jen Liu and Jia-Horng KaoInfection due to hepatitis B virus (HBV) is a global public health issue. With effective treatment, it is possible to prevent disease progression to cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients. Several viral factors have been documented to be associated with disease progression and treatment response, including HBV genotype and several naturally occurring HBV mutants, such as precore stop codon Read More
-
-
-
MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Authors: William Xu, Qi Zhao Wang, Qi Cui and Ruian XuMicroRNAs (miRNAs), a class of short endogenous RNAs, act as post-transcriptional regulators of gene expression. A vast literature has emerged over the past decade about miRNAs and their pivotal roles as negative regulators of gene expression in a wide array of (patho)physiological processes. Recent observations have revealed that many miRNAs are implicated in common human cancers through a variety of mecha Read More
-
-
-
Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward
The polymorphic cytochrome P450 2D6 (CYP2D6) enzyme, a member of the cytochrome P450 mixed-function oxidase system, is one of the clinically most important enzymes involved in the metabolism of drugs and other xenobiotics. This highly polymorphic enzyme exhibits vastly different phenotypes: poor metabolizers show no enzyme activity, whilst ultrarapid metabolizers exhibit a significantly higher activity. Bet Read More
-
-
-
REVIEWER ACKNOWLEDGEMENT
More LessThe reader will find below the list of guest referees who dedicated their time and expertise to the peer review process of the Journal over the past year. Rigorous, objective and timely peer review is crucial to sustain the high publication standards of the CPPM. We also recognize that pharmacogenomics and personalized medicine is a field of inquiry drawing from diverse disciplines and expert colleagues in different gl Read More
-
Volumes & issues
Most Read This Month
Article
content/journals/cppm
Journal
10
5
false
en
